We have measured specific binding of insulin-like growth factor I and growth hormone to renal plasma membranes from control, streptozotocin-diabetic, insulin-treated diabetic, uninephrectomised and combined diabetic-uninephrectomised male Wistar rats. Control, insulin-treated and uninephrectomised rats had similar body weights after 7 days (243_+2g), whereas diabetic and diabetic-uninephrectomised animals were significantly lighter (219+4 and 203 + 4 g, p < 0.05). Blood glucose concentrations were similar in the diabetic and diabetic-uninephrectomised animals (around 26 mmol/l) but significantly lower in the insulintreated group. Right kidney weight increased by 14% in the control, insulin-treated and sham-nephrectomised animals, by 33% in the diabetic group, 38% in the nephrectomised animals and 60% in the diabetic-nephrectomised group. The renal content of insulin-like growth factor I was similar and stable in the control, insulin-treated and sham-nephrectomised animals (208 + 14 ng/g wet weight) but rose to a peak of 669_+ 35 ng/g in the diabetic group (p <0.001), 871 + 34 ng/g in the nephrectomised animals (p < 0.001) and 1.012_+43 ng/g in the diabetic-uninephrectomised group
Renal hypertrophy occurs rapidly after the induction of experimental diabetes and in the remaining kidney following unilateral nephrectomy, a significant increase in kidney weight being seen after 4 days [1, 2] . Kidney growth is preceded by a rise in the renal content of insulin-like growth factor I (IGF-I) [2] [3] [4] . In experimental diabetes, both the increase in IGF-I and the rise in kidney weight are dependent on the severity of the diabetes [5, 6] and both can be prevented by treatment with insulin [2] . In both diabetes and after uninephrectomy, renal growth and the rise in content of IGF-I are prevented by the synthetic somatostatin analogue octreotide [3] . If these two growth stimuli of diabetes plus unilateral nephrectomy are combined, the resultant increase in kidney content of IGF-I and renal weight are additive [7, 8 I .
The source of the renal IGF-I is unclear. Traditionally it has been suggested that IGF-I is synthesised in the liver under the control of growth hormone (GH), and secreted into the circulation to exert its growth promoting effects on distant organs [9, 10] . However, the demonstration of mRNA for IGF-I [11, 12] , in many tissues, including the kidney, suggests that IGF-I may act in a paracrine or autocrine manner. IGF-I mRNA concentrations in the kidney are unchanged for the first 4 days following the induction of experimental diabetes [13] . Following unilateral nephrectomy, IGF-I mRNA levels have been reported as relatively increased [14] or unchanged [15] . Thus, the increased renal IGF-I may not be due to increased local transcription IGF-I receptors are found in kidney homogenates [16, 17] , and on mesangial [18] [19] [20] [21] [22] and tubular cells [21, 23] in tissue culture. If the increase in IGF-I after diabetes and uninephrectomy is due to increased uptake from the circulation, it might be expected that changes in IGF-I receptor number or affinity might be seen. We have therefore measured specific IGF-I and GH binding to renal plasma membranes after induction of diabetes, uninephrectomy and combined diabetes-uninephrectomy.
Materials and methods

Animals
Male Wistar rats (Mollegaards, Avlslab, Eiby, Denmark) of mean body weight 198g (range 184-218) were studied. Animals were housed three per cage in a room with 12:12 h (06.00-18.00 hours) artificial light cycle, temperature 21 + 2~ and humidity 55 + 2%. The animals had free access to standard rat fodder (Altromin, Lage, FRG) and tap water throughout the experiment. The animals were randomised into six groups matched for body weight: Group 1 control animals (n = 18); Group 2 diabetic animals (n = 50); Group 3 insulin-treated diabetic animals (n = 16); Group 4 uninephrectomised animals (n =40); Group5 sham uninephrectomised animals (n = 12); Group 6 uninephrectomised, diabetic animals (n = 50). Diabetes was induced on day 0 by intravenous injection of streptozotocin (55 mg/kg body weight) in acidic 0.154 mol/l NaC1, pH 4.0, after 12 h food deprivation. Left nephrectomy was performed via a flank incision. For sham nephrectomy, the left kidney was gently manipulated only. In group 6, streptozotocin was administered immediately following nephrectomy. Eighteen hours after the inj ection of streptozotocin, and daily thereafter, the animals were weighed, urinalysis was performed for glucose and ketones using Neostix 4 (Ames Limited, Stoke Poges, Slough, Buckinghamshire, UK) and tail-vein blood glucose determined by Haemoglucotest 1-44 and Reflolux II reflectance meter (Boehringer-Mannheim, Mannheim, FRG). Insulin treatment with long-acting heat-treated bovine Ultralente insulin (Novo, Bagsvaerd, Denmark) was begun 18 h after the administration of streptozotocin, when all diabetic animals had blood glucose levels > 18 mmol/1. The initial dose of insulin was 4--6 units, followed by 1-2 units daily depending on the blood glucose concentration. Fodder consumption was measured by housing animals from groups l, 2, 4 and 6 in metabolic cages for 24 h on days 1-2 and 3M.
On days 1,2, 3, 4 and 7, ten animats were killed from the diabetic, uninephrectomised and diabetic-uninephrectomised groups. Six 633 control animals were killed on days 0, 2 and 7, and six or eight rats from the sham-nephrectomised and insulin-treated diabetic groups on days 2 and 7. Under anaesthesia with sodium barbital (50 mg/kg), blood was drawn from the retroorbital venous plexus and serum stored at -20~ for later determination of IGF-I. Both kidneys were rapidly removed, cleaned, weighed and frozen in liquid nitrogen. The right kidney was used for determination of IGF-I content and the left for hormone binding studies.
Hormone binding studies
A full sequence IGF-I analogue was obtained from Amgen Biologicals, (Thousand Oaks, Calif., USA) IGF-II fiom Bachem, (Bubendoff, Switzerland) and GH from Nordisk, (Gentofte, Denmark). Binding of hormones to renal plasma cell membranes was performed by a modification of the method of Marshall et al. [24] . Membranes were prepared by homogenisation of the entire left kidney on ice in 3 mmol/1 imidazole in 300 mmol/1 sucrose, pH 8.0, containing 360 rag/1 PMFS, 4 g/1 EDTA, 40,000 U/1 Trasylol and 100 mg/1 badtracin. Homogenisation was by Ultra Turax homogeniser at 2400 rev/min for 10 s on two occasions. The homogenate was centrifuged at 2400 rev/min, 4~ for 10 rain and the supernatant spun at 33,000 g, 4~ for 30 min. The pellet was washed once before resuspension in Tris assay buffer, 25 mmol/1, pH 8.0, containing 10 mmol/1 MgC1, 100 mg/l bacitracin and 10 g/l bovine albumin. An aliquot was taken for protein determination by the Lowry method [25] and the rest of the homogenate frozen at -70~ until binding was assayed. Binding assays were performed at 4~ in Tris assay buffer described above, in Eppendorf tubes. To approximately 25 gg (for IGF-I binding) or 50 bLg (for GH binding) membrane protein was added increasing concentrations of cold IGF-I (to 800ng/ml) or GH (400 ng/ml) and approximately 0.07 pmol mono-iodo-r specific activity 2000 Ci/mmol (Amersham International, Aylesbury, Buckinghamshire, UK) or approximately 0.05 pmol monoiodoJ25I-GH, specific activity 2000 Ci/mmol (Nordisk). The reaction was incubated at 4~ for 18 h, conditions shown previously to maximise specific binding and minimise degradation of the labelled hormones. After termination of the reaction by the addition of 300 ~tl ice-cold assay buffer, the tubes were centrifuged at 4~ 2400 rev/min for 30 rain, the supernatant aspirated and the pellet washed twice with 300 gl assay buffer. The tips of the centrifuge tubes were cut off and the radioactivity in the pellet counted. Nonspecific binding, defined as the counts of 125I-1GF-I or ~25I-GH remaining bound in the presence of 800 ng/ml IGF-I or 400 ng/ml GH, was subtracted from the total binding to give specific binding. Scatchard and Hill plot analysis of the binding data was by the EBDA computer programme [26] . Specific binding was corrected to 25 ~tg membrane protein for IGF-I and to 50 gg for GH.
Characterisation of the IGF-I receptor was done by assessing the displacement of 125I-IGF-I by unlabelted IGF-I, IGF-II and insulin. Half-maximal displacement was 125 gg/1 for IGF-I, 595 gg/1 for IGF-II and 4200 gg/1 for insulin ( Fig. 1 ). This characteristic displacement pattern has been reported previously for IGF-I receptors in several tissue preparations, including renal tissue [17, 19, 22] . Degradation of ~a~I-IGF-I and 125I-GH in the binding assays was assessed as the precipitability by 20% trichloroacetic acid of aliquots of supernatants from binding assays and was less than 10%.
IGF-1 analysis
Renal tissue was extracted in 1 mol/1 acetic acid [6, 10] . After lyophilisation, the samples were redissolved in 40 mmol/1 phosphate buffer, pH 8.0 and stored at -20~ until assay. Serum was extracted in acetic acid-methanol [27] . The IGF-I radioimmunoassay used IGF-I antibody UB286 (raised by LE Underwood and JJ van Wyk, Paediatric Endocrinology, University of North Carolina, Chapel Hill, NC, USA) donated by the US National Hormone and Pituitary Program. 
Statistical analysis
Results are expressed as mean + SEM. Differences within and between groups were assessed by analysis of variance with correction for multiple testing, using the Statistical Package for the Social Sciences [28] .
Results
Body weight
Control, insulin-treated and sham-nephrectomised animals gained weight at similar rates during the study (Table 1 ). In the diabetic group, body weight decreased from 198+3g on day0 to 191+1g on day2 (p <0.05), but thereafter increased to 219 _+ 4 g on day 7 (Fig.2) . The body weight of the diabetic animals was significantly less than that of the control and insulin-treated animals at all time points from day 1 onwards. Nephrectomised animals initially lost weight, so that on day 2 they were significantly lighter than control and sham-nephrectomised animals (193 + i vs 208 + 3 and 205 _+ 2 g, p < 0.05 for both). However, by day 7, body weight of the nephrectomised animals was identical to that of control and sham-operated animals. In the diabetic-nephrectomised animals, body weight reached a nadir on day 2, and at all time-points body weight was significantly less than in the control, diabetic and nephrectomised animals.
Blood glucose
Eighteen hours after the injection of streptozotocin, blood glucose was identical in the diabetic and insulin-treated animals (23.2 + 0.7 and 23.5 +_ 0.9 mmol/1). In the diabetic group, blood glucose remained around 26 mmol/1 for the duration of the experiment (Fig. 2) . After initiation of in- 
Renal IGF-I content
The IGF-I content of the right kidney, expressed as ng IGF-I/g wet tissue weight, was 208 + 14 ng/g in the control animals on day 0 and remained similar in the control, insulin-treated and sham-nephrectomised animals throughout. In the diabetic group, the renal content of IGF-I increased to 669 + 35 ng/g on day 2 (p < 0.001), significantly higher than in control (217 + 20 ng/g;p < 0.001) and insulin-treated animals (268+41ng/g; p <0.01; Fig. 3 ). The kidney IGF-I content remained higher in the diabetic group than in control and insulin-treated animals for the duration of the study. Similarly, in the nephrectomised and diabetic-nephrectomised animals, renal content of IGF-I rose to 871 + 34 ng/g and 1012 + 43 ng/g respectively on day 2 (p < 0.001 for both) and remained elevated above control, insulin-treated and sham-nephrectomised animals throughout. In the diabetic-nephrectomised animals, the kidney content of IGF-I on day 2 was significantly greater than in the diabetic and nephrectomised animals (p < 0.05 for both).
Serum IGF-I
Serum IGF-I was 1023 + 53 rag/1 in the control group on day 0 and was similar in all groups at all time points throughout the study.
sulin therapy, blood glucose fell to normal values in the insulin-treated group, only being significantly greater than in the normal animals on day3 (9.2+1.0 vs 4.9 + 0.2 retool/l, p < 0.05). In the combined diabetic-nephrectomised animals, blood glucose was identical to that in the diabetic group at all time points.
Right kidney weight
The right kidney weight increased in a similar manner in control, sham-nephrectomised and insulin-treated diabetic animals, the increase being around 14% (Table 1 ). There was a 33% increase in the wet weight of the right kidney from the diabetic animals over the course of the study (Fig. 3) . In the diabetic group, the right kidney weight was significantly different from that in the insulintreated group on day 2 (824 + 14 mg vs 768 + 15 rag, p < 0.05) and significantly different to that in the insulintreated and control animals on day 7 (989 + 25 vs 828 + 20 and 849 + t8 rag, p < 0.01). The right kidney weight in the
IGF-I binding
In all groups of animals, analysis of the binding of IGF-I revealed linear Scatchard and Hill plots, with Hill coefficient 0.99, suggesting one class of receptors and non-cooperativity (Fig.4) . Maximal binding to renal plasma membranes (Bm~) was 8.2_+ 1.4 x 10 -1~ mol/1 per 25 gg membrane protein on day 0 in the control animals and remained constant throughout (Fig. 5) . Bmax decreased from the baseline value in the diabetic group to 5.2 _+ 0.7 x 10-11 tool/1 per 25 btg membrane protein on day 1 (p < 0.01) but thereafter was similar to values in the control group. In the insulin-treated animals, Bm~ increased to 11.0_+ 1.1 x 10 -11 mol/1 per 25/.tg membrane protein on day7, compared to 7.0+0.8 in the control group (p < 0.01) and 8.0 + 0.5 in the diabetic group (p < 0.01). Bm~x in the nephrectomised animals was identical to the control and diabetic animals throughout. In the shamoperated animals, Bm~x rose, so that on day 7 it was significantly higher than in control and nephrectomised animals (12.0 + 1.1 vs 7.0 • 0.8 and 6.0 _+ 0.5 x 10 ~ mol/l per 25 gg Affinity constant (Karl) was 7.8 + 0.3 • 1081/mol in the control group on day 0 and was unchanged in the control, nephrectomised, diabetic and combined diabetic-nephrectomised animals for the 7 days. In addition, the affinity constant of 7.79 x 108 1/mol reported here is very similar to previously reported values [19, [21] [22] [23] , suggesting that the specific IGF-I binding measured here is similar to that on which others have reported. In the insulintreated group, K~ff decreased to 6.1 + 0.1 x 108 1/mol on day 7 and to 5.5 + 0.5 in the sham-nephrectomised animals (p < 0.05 for both groups vs control and nephrectomised animals).
GH binding
As (Fig. 4) . Bmax was 7.8 + 0.7 x 10-t2 mol/1 per 50 ~tg membrane protein on day 0 in the control animals and remained similar in control, sham-nephrectomised, nephrectomised and insulin-treated animals for the duration of the experiment (Fig.5) . In the diabetic and combined diabetic-nephrectomised animals, Bmax fell to 3.1 + 0.6 and 2.8 + 0.2 x 10 -~2 mol/1 per 50 gg membrane protein on day 7 (p < 0.001 compared to control, insulintreated and nephrectomised animals). Affinity constant was 4.4 + 0.3 x 109 1/mol in the control group on day 0 and remained similar in all groups throughout the experiment.
Fodder consumption
In the diabetic, nephrectomised and diabetic-nephrectomised animals, fodder consumption on day 1-2 was less than that of the control animals (p < 0.05 for all; Fig. 6 ). However, by day 3-4, consumption had returned to that seen in the control animals in all three experimental groups. 
Discussion
We have shown similar IGF~I binding to renal plasma membranes in diabetic, uninephrectomised, uninephrectomised-diabetic and control animals, simultaneously with an acute and sustained rise in the renal content of IGF-I in the experimental animals only. The lack of prolonged change in the binding data suggests that this rise in the renal content of IGF-I is not due to increased uptake of IGF-I by renal cells, either from the systemic or local circulation or from urine. Our results contrast with a recent study reporting an increase in IGF-I binding to similar renal membrane preparations 14 days after induction of streptozotocin diabetes, with an increase in the IGF-I receptor mRNA levels [29] . However, the IGF-I content of the kidney homogenates was decreased and the IGF-I peptide mRNA levels unchanged. Taken together, these studies suggest that IGF-I binding to renal cells after induction of diabetes is time-dependent. In the initial phase, the IGF-I content is increased and binding unchanged. Later, as the IGF-I content falls, synthesis of the receptor and receptor binding are increased, perhaps as a secondary phenomenon. The transient decline in maximum specific binding in the diabetic group 24 h after injection of streptozotocin may be related to acute hypoinsulinaemia. Conversely, in the insulin-treated animals, there was a rise in the maximum specific binding and a fall in the affinity constant. It is likely that the insulin-treated animals were hyperinsulinaemic and that this was the cause of the changes in IGF-I binding. Insulin is known to regulate IGF-I binding. In human mesangial cells grown in tissue culture, addition of 10-100 ng/ml insulin to the culture medium resulted in enhancement of specific IGF-I binding [22] . Alternatively, hyperinsulinaemia will lower the serum levels of IGFbinding protein I, perhaps making more IGF-I available for cellular uptake and increasing the maximum binding [30] .
There was a pronounced and sustained reduction in the specific binding of GH in the untreated diabetic and combined uninephrectomy-diabetic groups, with no change in 637 the affinity constant. Binding in the insulin-treated and uninephrectomised groups was similar to that in control animals throughout. These data suggest that the rise in the renal content of IGF-I in the experimental animals is not under growth hormone control. It has been suggested that the effects of GH on renal function are mediated by IGF-I, but changes in functional parameters appear to occur independently to changes in renal size [31] . Recently, it has been reported that concentrations of the mRNA for the GH receptor are unchanged in kidney and liver in diabetes [32] . Thus the decline in maximum specific binding of GH in the diabetic animals may be due to internalisation of the GH receptor or alterations in recycling, rather than to decreased synthesis. An alternative explanation for the renal GH binding changes reported here is downregulation secondary to changes in serum GH concentrations. Mean serum growth hormone concentrations fall rapidly in streptozotocin diabetes, with loss of the secretory pulses [33J. The similar decline in maximum GH binding in the combined uninephrectomy-diabetic group but not in the uninephrectomy group supports the concept that changes in GH binding are secondary to the metabolic consequences of diabetes.
It is unclear why the maximum specific binding and affinity constant for IGF-I changed in the sham-nephrectomised animals. The sham and uninephrectomised animals were handled in an identical manner peri-operatively. It may be that the stress-induced rise in hormones such as glucagon and cortisol enhances IGF-I binding in the sham nephrectomised animals, whilst in the uninephrectomised animals this rise is counterbalanced by a fall in binding due solely to the removal of one kidney.
The lack of change in the IGF-I binding parameters in all three experimental groups suggests that in each situation, the rise inthe renal content of IGF-I is not related to changes in the IGF-I receptor. This is in keeping with the concept that the increase in the renal content of IGF-I cannot be accounted for by increased cellular uptake, either from the systemic or local circulation or from urine. An alternative explanation is for an increased local synthesis of IGF-I. We have recently demonstrated in an identical model, that IGF-I mRNA levels in the kidney do not change for the first 4 days of experimental diabetes [13] . Thus, alternative mechanisms such as an alteration in the mRNA steady-state or altered post-transcriptional processing may account for the rise in the IGF-I. The mechanisms accounting for the increased renal content of IGF-I may not be similar in diabetes and after uninephrectomy. Fagin and Melmed have recently reported a relative increase in IGF-I mRNA in the remaining kidney after unilateral nephrectomy [14] . However, using a more specific and sensitive solution hybridisation assay, another group have not shown any change in IGF-I mRNA levels after unilateral nephrectomy [15] . Thus, it is not clear whether the rise in the renal content of IGF-I after uninephrectomy may be accounted for by increased local synthesis.
Although IGF-I receptors have been found on many cell types of the kidney [19] [20] [21] [22] , the changes in IGF-I content seen during renal growth may be localised to specific areas of the nephron. In the normal rat kidney, IGF-I has been shown by immunohistochemical staining to be confined to the cells of the medullary collecting duct and those parts of the thin loop of Henle in the outer medulla [15, [34] [35] [36] . After unilateral nephrectomy, positive staining is seen in the remaining kidney in all parts of the collecting ducts and the thin loop of Henle [15, 34] . It may be that by studying homogenates of whole kidneys, small but very important changes in IGF-I synthesis or uptake in very precisely localised areas of the nephron are not detected. Further studies should perhaps examine specific areas of the nephron separately. In human diabetic nephropathy, expansion of the mesangium is thought to be important in the decline of renal function [37] . The role of IGF-[ in mesangial growth is thus also of interest.
In summary, we have shown no change in specific binding of IGF-I to renal plasma membranes after induction of diabetes or uninephrectomy, suggesting that the rise in the renal content of IGF-I seen in both these situations is not due to increased uptake of IGF-I from the circulation. Specific binding of GH fell in the diabetic group, probably secondary to the declining serum GH concentrations.
